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ABSTRACT 
Background: ADA has cut-off value for IGT (140-200 mg/dL) but has a lower cut-off value for IFG (100-125 mg/dL) and has additional 
hemoglobin A1c (HbA1c) based criteria of a level of 5.7% to 6.4% for the definition of prediabetes. Due to progressive nature of prediabetes, 
dual drug therapy produces additive effects, allows the use of submaximal doses, and less side effects of individual agents. Therefore, the 
present study was designed to study the effect of voglibose in comparison to pioglitazone on glycemic control as an add-on drug in prediabetes 
patients whose glycemic status was uncontrolled with metformin alone. 
Methods: The present study was open, randomized, parallel group comparison of two active treatment groups over a period of six months. 
Sixty-seven patients of either sex in the age group of 30-60 years, suffering from prediabetes, with FBG: 100-125 mg/dl and PPBG:140-200 
mg/dl as per ADA were selected at randomly. The effect of FDC of Voglibose with Metformin and Pioglitazone with Metformin were observed on 
various parameters of Glycemic Triad (FBG, PPBG, HOMA-IR, HbA1c and Serum Insulin). 
Results: At the end of 6 months it was observed that though both FDC of Voglibose with Metformin and Pioglitazone with Metformin reduced 
Glycaemia Statistically significantly but Pioglitazone with Metformin caused a significantly greater percentage change in Glycaemia as 
compared with Voglibose with Metformin. Few side effects were observed with Voglibose but not with Pioglitazone. 
Conclusions: Though Voglibose with Metformin and Pioglitazone with Metformin were equally effective in lowering Glycemia yet Pioglitazone 
with Metformin showed better results in improving glycaemia, as compared to Voglibose with Metformin. Pioglitazone with Metfo rmin had 
minimal side effects as compared to Voglibose with Metformin. 
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INTRODUCTION: 
Prediabetes is defined according to American Diabetes 
Association (ADA) criteria an impaired fasting glucose (IFG; 
fasting glucose of 100–125 mg/dL), impaired glucose 
tolerance (IGT; two-hour postprandial glucose of 140–199 
mg/dL), or both. There is substantial evidence to suggest 
that even at these blood glucose levels, significant risk exists 
for both micro- and macrovascular complications. [1]  
The overall prevalence of prediabetes in all 15 states of India 
was 7.3%. Overall, the prevalence in urban areas 11.2% was 
about double that in rural areas 5.2%. Compared with their 
rural counterparts, men in urban areas had prediabetes of 
1.84 and women in urban areas had an odds ratio of 1.58, 
after adjustment for age, BMI, systolic blood pressure, 
socioeconomic status (SES), and smoking status. [2] 
Insulin resistance, a major abnormality underlying 
prediabetes and type 2 diabetes mellitus (T2DM) and 
obesity, is defined as the pathophysiological condition of 
reduced insulin responsiveness in liver, muscle, and adipose 
tissue. [3] Insulin resistance plays a key role in the 
pathogenesis of diseases by causing an imbalance between 
factors that favour hepatic lipid accumulation, such as lipid 
influx and de novo lipogenesis (DNL), and factors that 
Mubeen et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(4):92-99 
ISSN: 2250-1177                                                                                  [93]                                                                                 CODEN (USA): JDDTAO 
ameliorate lipid accumulation, such as lipid export or 
oxidation. [4] 
Pioglitazone, is an insulin-sensitizing (Thiazolidinedione’s) 
TZDs, is widely used for the treatment of type 2 diabetes. 
TZDs are known to activate peroxisome proliferator-
activated Receptor- γ (PPAR- γ). [5] PPAR- γ activation by 
pioglitazone lead to increases insulin sensitivity in liver, fat 
and skeletal muscle cells, increases peripheral and 
splanchnic glucose uptake and decreases hepatic glucose 
output. [6] Pioglitazone is dependent on the presence of 
insulin in order to exert its beneficial effects and may help 
preserve β-cells of the islets of Langerhans, but does not act 
as an insulin secretagogue. [7] Pioglitazone promotes lipid 
storage and redistribution from visceral to subcutaneous 
deposits, resulting in an increase in whole body adiposity, 
while promoting the differentiation of adipocytes. [8]  
Voglibose is an alpha-glucosidase inhibitor used for lowering 
post-prandial blood glucose levels in people with type-2 DM. 
It reduces intestinal absorption of starch, dextrin, and 
disaccharides by inhibiting the action of α-glucosidase in the 
intestinal brush border. Inhibition of this enzyme catalyzes 
the decomposition of disaccharides into monosaccharides 
and slows the digestion and absorption of carbohydrates. α - 
Glucosidase inhibitors do not stimulate insulin release and 
therefore do not result in hypoglycemia. [9,10] 
Metformin, a biguanide class of oral hypoglycemic agents, is 
the first line drug for the treatment of type 2 diabetes 
mellitus. [11] Metformin is used clinically for the treatment of 
diabetes, and its mechanism of actions include the following: 
(1) lowers plasma glucose levels by inhibiting 
gluconeogenesis in liver, (2) decreasing the intestinal 
absorption of glucose, and (3) improving insulin sensitivity 
by increasing peripheral glucose uptake and utilization. [12] 
Additionally, metformin has a variety of pleiotropic effects 
including improved lipid and cholesterol metabolism, 
decreased inflammation and inhibition of cell growth. [13] (4) 
Increases plasma levels of glucagon-like peptide 1 (GLP-1) is 
a member of the incretin family of peptide hormones release 
incretin from the gut in response to ingested glucose. It 
induces insulin release from pancreatic β-cells, retards 
gastric emptying, inhibits glucagon release from α cell, and 
produces a feeling of satiety. [14] 
Clinically, it has been proposed that a combination of 
changes in lifestyle modification with pharmacological 
approaches could be a more effective strategy for the 
management of prediabetes. In addition, unlike their 
relatively lean counterparts, prediabetes patients require 
specific dosing for a curative response to treat. On these 
lines, we hypothesized that glycemic control in prediabetes 
interventions in conjunction with Fixed Dose Combination 
(FDC) of Voglibose with Metformin versus Pioglitazone with 
Metformin therapy could have a significant positive impact 
on the management of prediabetes. We believe that, in FDC, 
these modalities represent the most effective means for 
delaying or even preventing the onset of diabetes in a 
prediabetes population. This paper concludes with a brief 
example in which these principles are applied to a 
hypothetical patient. 
Therefore, in the present study, we were targeted Glycemic 
control in prediabetes subjects and confirmed the effects of 
combined drugs, which group reduces blood glucose level, 
HOMA-IR, HbA1c, Serum Insulin was the primary outcome of 
these metabolic diseases. 
The secondary end point of the study was to evaluate the 
safety of FDC which group has fewer side effects. 
MATERIAL AND METHODS: 
Study design and settings: 
The present study was Prospective, Randomized, Open-label, 
Single Center, and Parallel-group, evaluating comparative 
effect of FDC of Pioglitazone with Metformin combination 
versus Voglibose with Metformin in Prediabetes with obese 
patients over a period of six months in outpatient 
department of Medicine in MGM Hospitals and College, 
Aurangabad. This study was conducted after institutional 
ethical committee approval, informed consent regulations, as 
per Declaration of Helsinki, ICH good Clinical Practice (GCP) 
guidelines and the ICMR guidelines for Biomedical Research 
on Human Subjects, 2006. The total duration of study was 2 
Years. 
Inclusion criteria: Prediabetes Patients diagnose according 
to American Diabetes Association (ADA) criteria (IGT; two-
hour postprandial glucose of 140–199 mg/dL and HbA1c 5.7-
6.4%) in the age group of 30-60 years of either sex, all 
patients provided written, vernacular, witnessed, informed 
consent to participate in the study, Patients willing to take 
medications as directed and willing to come for the follow-
up. 
Exclusion criteria: Patients with history of Type 1 and Type 
2 DM, with acute medical emergencies like Diabetic 
Ketoacidosis, Polycystic ovarian disease, Liver disease, 
Kidneys disease, Cardiovascular disease, any Microvascular 
complication, with chronic Gastrointestinal disease, 
concomitant with steroid therapy and history of 
hypersensitivity to test drug, pregnant and lactating women 
also excluded from the study. 
Intervention drugs: 
After meeting the inclusion criteria, patients were 
randomized by a computer-generated randomization 
sequence into two Groups, each consist of 67 patients. In 
Group A: FDC of Tab. Voglibose 0.2 mg + Metformin 500 mg 
BD orally was given for 6 months and Group B: FDC of Tab. 
Pioglitazone 7.5 mg + Metformin 500 mg BD orally for 6 
months was given and the patients were directly started at 
this dose. To check compliance and ensure regular 
medication by the patient, a log book was checked regularly 
which was given to each patient. 
On the start of the study, (Day 0), after taking the medical 
history, demographic details, physical measures (waist 
circumference, body mass index (BMI)), general and 
systemic examination of the patients, routine laboratory 
investigations were sent. The baseline Fasting Blood Glucose 
(FBG), Post-prandial Blood Glucose (PPBG), Serum insulin, 
HbA1c and Homeostasis model assessment-insulin 
resistance (HOMA-IR) were measured. 
Patients were given a 15 days’ supply of either drug with 
proper directions and asked to report back after 15 days. 
Initially patients were followed after 15 days and 
subsequently every month up to 6 months.  
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Study Flow Chart: 
 
 
The participants through the study including randomization, 
medications and drop outs are shown in flowchart 1. 
Statistical Analysis: 
The collected data was compiled in MS Excel sheet for 
analysis in Statistical Package for the Social Sciences (SPSS) 
version 20th was applied. The qualitative data was 
represented in the form of frequencies and percentage also 
represented in visual impression like bar diagram. 
Quantitative data was represented in the form of mean and 
standard deviation. To check significance difference between 
baseline, after three months and six months effect of Group 
A Versus Group B in prediabetes patient. An unpaired ‘t’ test 
was applied for two different Groups and paired ‘t’ test was 
applied for same Group/ within Group and also quantitative 
data was represented in the form of bar diagram. The level 
of significance was determined as its ‘p’ value with p < 0.05 
was taken as significant at 5% significance level, p < 0.01 
was taken as significant at 1% significance level and p < 
0.001 was taken as highly significant, p> 0.05 was taken as 
insignificant. Drop outs were not considered in the analysis. 
RESULTS: 
Total 150 patients with prediabetes were screened out of 
144 eligible patients were randomized equally into two 
treatment Groups who were randomized in the study. In 
Group A: 5 patients and in Group B: 5 patients were lost 
from study. Both the Groups were similar in demographic 
profile at baseline as shown in flowchart 1. 
In table 1 and figure 1: In both the Groups, maximum 
number of patients was in the age Group of 51-60 years and 
least number of patients were within ≤40 years of age. Mean 
age in Group A was 51.10 ± 6.62 and in Group B was 52.29 ± 
6.55. There was no statistically significant difference in age 
distribution between the two groups. 
 
Table 1: Comparison of Mean Age in Groups: 
Age-Group Group A 
[Met + Pio] 
Group B 
[Met + Vog] 
No Percentage No Percentage 
≤40 year 04 5.9% 02 2.9% 
41--50 26 38.8% 26 38.8% 
51--60 37 55.2% 39 58.2% 
Total 67 100 67 100 
Mean±SD 51.10±6.62 years 52.29±6.55 years 
Z-value                          1.04 
 
 
 
 
Mubeen et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(4):92-99 
ISSN: 2250-1177                                                                                  [95]                                                                                 CODEN (USA): JDDTAO 
 
Figure 1: Distribution of Age-group in Group A and B 
Table 2: Gender difference between Group A and Group B 
 Group A Group B Chi-Square test 
p=value n=67 (%) n=67 (%) 
Male 43 64.17 46 68.65 0.112 
Female 24 35.83 21 31.35 
Total 67 100 67 100 
 
 
Graph 2: Gender difference between Group A and Group B 
The table 2 and graph 2 reflects that 134 prediabetes 
patients selected, in Group A: 43 were male (64.17%) while 
24 were female patients (35.83%). In Group B consisted of 
46 male patients (68.65%) and 21 female patients (31.35%). 
There was no statistically significant difference in number of 
patient from Group A and Group B patients (0.112).
 
Table 3: Comparison of FBG between Group A and Group B at baseline, after 3 months and after 6months (Unpaired 
test): 
 Group A 
Mean±SD 
Group B 
Mean±SD 
z-value p-value 
FBS Baseline 103.14±3.38 104.15±4.38 0.07 P=0.150 ns 
After 3 Months 92.41±5.42 89.92±6.70 2.72 P=0.016 * 
After 6 Months 80.85±7.51 78.47±7.20 3.01 P=0.029 * 
Mean ± SD in mg/dl, SD: Standard deviation, NS: Not significant, *: Significant, **: Highly Significant. 
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Table 4: Comparison of Mean Differences of Fasting Blood glucose level (mg/dl) at baseline, after 3 months and after 6 
months in Groups analyzed by paired ‘t’ test 
FBS Group A Group B 
Mean 
Difference 
t-value p-value Mean 
Difference 
t-value p-value 
Baseline vs  
After 3 Months 
10.73 12.87 P<0.0001 ** 14.22 14.46 P<0.0001 ** 
After 3 Months vs. 
After 6 Months 
11.56 13.26 P<0.0001 ** 11.44 12.75 P<0.0001 ** 
Baseline vs  
After 6 Months 
22.29 21.86 P<0.0001 ** 25.67 25.49 P<0.0001 ** 
NS: Not significant, *  p<0.05 significant,  **  p<0.001 highly significant 
 
Fasting Blood Glucose levels within both the groups showed 
statistically significant reduction over a period of 6 months. 
But on comparison between Group A versus Group B 
patients, there was a statistically significant difference in 
mean percentage change in FBG levels at the end of 3rd 
month (p< 0.05) and this difference was statistically highly 
significant at 6th month of study period (Table 3 and 4, p< 
0.001). 
 
Table 5: Comparison of Mean Post Prandial Blood Glucose level between Group A and Group B at baseline, after 3 
months and after 6months (Z- test): 
 Group A 
Mean±SD 
Group B 
Mean±SD 
Z-value p-value 
PPBG Baseline 174.85±15.22 174.44±16.62 0.14 P=0.892 ns 
After 3 Months 153.76±15.75 161.11±15.68 2.70 P=0.017 * 
After 6 Months 124.08±9.96 146.59±16.83 9.42 P<0.0001 ** 
Mean ± SD in mg/dl, SD: Standard deviation, NS: Not significant, 
*  p<0.05 significant,  **  p<0.001 highly significant 
 
Table 6: Comparison of Mean Differences of Post-Prandial Blood glucose level (mg/dl) at baseline, after 3 months and 
after 6 months in Groups analyzed by paired ‘t’ test: 
PPBG Group A Group B 
Mean 
Difference 
t-value p-value Mean 
Difference 
t-value p-value 
Baseline vs After 3 Months 
21.08 25.15 
 
P<0.0001 ** 
13.32 12.51 
 
P<0.0001 ** 
After 3 Months vs. After 6 Months 
29.67 12.80 
 
P<0.0001 ** 
27.85 22.09 
 
P<0.0001 ** 
Baseline Vs After 6 Months 
50.76 22.40 
 
P<0.0001 ** 
22.44 10.83 
 
P<0.0001 ** 
NS: Not significant, *  p<0.05 significant,  **  p<0.001 highly significant 
 
Postprandial blood glucose levels within both the groups 
showed statistically significant reduction over a period of 6 
months. On comparison between Group A versus Group B 
patients, a statistically significant difference in mean 
percentage change in PPBG levels was observed at the end of 
3rd month (p< 0.05) and a statistically highly significant 
difference was observed at the end of 6th month (Table 5 
and 6, p< 0.001).  
 
Table 7: Comparison of Mean HOMA-IR between Group A and Group B at baseline, after 3 months and after 6months 
(Z- test): 
 Group A 
Mean±SD 
Group B 
Mean±SD 
z-value p-value 
HOMA-IR Baseline 3.82±0.63 3.87±0.67 3.51 P=0.63 ns 
After 3 Months 3.16±0.52 2.87±0.47 5.86 P<0.0001 ** 
After 6 Months 2.38±0.44 2.12±0.39 9.14 P<0.0001 ** 
Mean ± SD in mg/dl, SD: Standard deviation, NS: Not significant, 
*  p<0.05 significant,  **  p<0.001 highly significant 
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Table 8: Comparison of Mean Differences of HOMA-IR level at baseline, after 3 months and after 6 months in Groups 
analyzed by paired ‘t’ test: 
HOMA-IR Group A Group B 
Mean 
Difference 
t-value p-value Mean 
Difference 
t-value p-value 
Baseline vs. After 3 Months 0.65 14.13 P<0.0001 ** 1.00 9.63 P<0.0001 ** 
After 3 Months vs. After 6 Months 0.78 16.60 P<0.0001 ** 0.74 20.40 P<0.0001 ** 
Baseline vs. After 6 Months 1.44 26.33 P<0.0001 ** 1.74 17.46 P<0.0001 ** 
NS: Not significant, *  p<0.05 significant,  **  p<0.001 highly significant 
Homeostasis model assessment-insulin resistance (HOMA-
IR) within both the groups showed statistically significant 
reduction over a period of 6 months. On comparison 
between Group A versus Group B patients, a statistically 
highly significant difference in mean percentage change in 
HOMA-IR levels was observed at the end of 3rd and 6th month 
(Table 7 and 8, p< 0.001). 
  
Table 9: Comparison of Mean HbA1c between Group A and Group B at baseline, after 3 months and after 6months (Z- 
test): 
 Group A 
Mean±SD 
Group B 
Mean±SD 
z-value p-value 
HbA1c Baseline 6.25±0.14 6.24±0.14 0.22 P=0.416 ns 
After 3 Months 5.81±0.17 5.62±0.21 2.64 P<0.0001 ** 
After 6 Months 5.31±0.19 5.14±0.11 4.10 P<0.0001 ** 
Mean ± SD in mg/dl, SD: Standard deviation, NS: Not significant, 
*  p<0.05 significant,  **  p<0.001 highly significant 
Table 10: Comparison of Mean Differences of HbA1c level at baseline, after 3 months and after 6 months in Groups 
analyzed by paired ‘t’ test 
HbA1C Group A Group B 
Mean 
Difference 
t-value p-value Mean 
Difference 
t-value p-value 
Baseline vs. After 3 
Months 
0.44 16.13 P<0.0001 ** 0.61 19.36 P<0.0001 ** 
After 3 Months vs. 
After 6 Months 
0.50 15.49 P<0.0001 ** 0.48 16.69 P<0.0001 ** 
Baseline vs. After 6 
Months 
0.94 31.07 P<0.0001 ** 1.09 49.87 P<0.0001 ** 
NS: Not significant, *  p<0.05 significant,  **  p<0.001 highly significant 
HbA1c levels within both the groups showed statistically 
significant reduction over a period of 6 months. But on 
comparison between Group A versus Group B patients, there 
was statistically highly significant difference in mean 
percentage change in HbA1C at the end of 3rd and 6th month 
of study period (Table 9 and 10, p< 0.001).  
 
Table 11: Comparison of Mean Serum Insulin level between Group A and Group B at baseline, after 3 months and after 
6months (Z- test): 
 Group A 
Mean±SD 
Group B 
Mean±SD 
z-value p-value 
S. Insulin Baseline 15.01±2.35 15.05±2.40 0.54 P=0.913 ns 
After 3 Months 13.88±2.09 12.99±2.09 6.24 P<0.017 * 
After 6 Months 11.94±1.90 10.97±1.67 8.19 P<0.003 * 
Mean ± SD in mg/dl, SD: Standard deviation, NS: Not significant, 
*  p<0.05 significant, ** p<0.001 highly significant 
Table 12: Comparison of Mean Differences of Serum Insulin level at baseline, after 3 months and after 6 months in 
Groups analyzed by paired ‘t’ test: 
S. Insulin Group A Group B 
Mean 
Difference 
t-value p-value Mean 
Difference 
t-value p-value 
Baseline vs. After 3 
Months 
1.13 8.55 P<0.0001 ** 2.07 5.04 P<0.0001 ** 
After 3 Months vs. 
After 6 Months 
1.94 13.32 P<0.0001 ** 2.01 14.88 P<0.0001 ** 
Baseline vs. After 6 
Months 
3.07 18.77 P<0.0001 ** 4.08 11.03 P<0.0001 ** 
NS: Not significant, *  p<0.05 significant,  **  p<0.001 highly significant 
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Serum Insulin levels within both the groups showed 
statistically significant reduction over a period of 6 months. 
But on comparison between Group A versus Group B 
patients, a statistically significant difference in mean 
percentage change in serum insulin levels was observed at 
the end of 3rd month (p< 0.05) and a statistically highly 
significant difference was observed at the end of 6th month 
(Table 11 and 12, p< 0.001).  
DISCUSSION: 
The present comparative study was conducted to assess the 
efficacy and safety of fixed does Combination (FDC) of 
Voglibose and Metformin versus Pioglitazone and Metformin 
in urban prediabetes patients in India. In the present study 
67 patients of prediabetes were given Voglibose and 
Metformin versus Pioglitazone with Metformin in Group A 
and Group B respectively. There were no cases of 
hypoglycemia, weight gain and edema reported in the 
present study. It is not so costly as compared with other 
drugs. It is easily available even in remote areas. No 
significant drug interactions are there and usually well 
tolerated. No dose adjustment was needed and they improve 
glycemic control.  
Chronic hyperglycemia is an important predictor of the 
development of diabetic complications like microvascular, 
macrovascular and acute metabolic complications. Chennai 
urban population study (CUPS) and the Chennai Urban Rural 
Epidemiology Study (CURES) provided valuable data from 
India on diabetic complications. (15, 16) The Diabetes 
Prevention Program (DPP) was a 27-center randomized 
clinical trial to determine that both the lifestyle intervention 
and pharmacological therapy (metformin) were effective in 
preventing or delaying the onset of diabetes from 
prediabetes in individuals with impaired glucose tolerance 
(IGT) who are at high risk for the disease. (17) 
In our study significant decrease in FBG, PPBG, HOMA-IR, 
HbA1c and Serum Insulin was found in both Voglibose and 
Metformin versus Pioglitazone with Metformin. The 
reduction in various parameters was perceived in 
consecutive sequence commiserating with duration of study 
i.e. at baseline, 3rd and 6th months. But on contrast, 
arrangement of FDC of Pioglitazone with Metformin resulted 
in greater decline in FBG, HOMA-IR, HbA1c, and Serum 
Insulin than Voglibose with Metformin. Whereas only PPBG 
was reduced significantly in FDC of Voglibose with 
Metformin than Pioglitazone with metformin. Similarly, 
study conducted by Amita Jindal et al. supports with our 
study. (18) 
These guidelines await outcome validation but offer a strong 
rationale for combination therapy in a high-risk population. 
Rational behind combination of this two drugs are impact on 
beta cells, increases insulin sensitivity, further reduction of 
insulin resistance with these FDC of two drugs could enhance 
durability of glycemic control, additionally decreasing the 
intestinal absorption of glucose and preserve β-cells of the 
islets of Langerhans. 
On the other hand, fixed does Combination (FDC) of two 
drugs are mainly used to reduce numbers of pill burden, 
preferably offer synergistic effect, reduced side effects, to 
optimize the target of diseases, offers increased 
bioavailability of antidiabetic drugs in relevant to their 
simultaneous administration as separated pills, thus reduced 
the number of pills to take at a time. (19-24) It is cheaper to 
acquire a FDC drug than to acquire single drug individually. 
(25) This article examines the use of FDC’s therapy for the 
treatment of prediabetes and it gives ideas to prescribers, 
payers and patients. 
Among the side effects, weakness was perceived with both 
the drugs whereas abdominal pain, flatulence, diarrhea, 
headache, sweating and hot flushes were perceived only in 
Voglibose with Metformin not in Pioglitazone with 
Metformin, thereby presenting that Pioglitazone is a safer 
drug because it causes fewer side effects as compared with 
Voglibose. So, Pioglitazone may be the ideal add on drug 
along with metformin in the treatment of prediabetes and 
type 2 diabetes mellitus. It is found quite effective in patients 
of urban setting. If there is no question of affordability, then 
it could be good alternative options as FDC of Prediabetes 
and anti-diabetic drugs. 
CONCLUSION  
Though Pioglitazone with Metformin showed better results 
in controlling glycemic profile (FBG HOMA-IR, HbA1c, and 
Serum Insulin) as compared with Voglibose with Metformin. 
Moreover, Pioglitazone had minimal side effects as compared 
to Voglibose group. 
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